PMID- 24947203 OWN - NLM STAT- MEDLINE DCOM- 20151201 LR - 20150225 IS - 1578-8989 (Electronic) IS - 0025-7753 (Linking) VI - 144 IP - 6 DP - 2015 Mar 15 TI - N-terminal Pro-B type natriuretic peptide as long-term predictor of death after an acute pulmonary embolism. PG - 241-6 LID - S0025-7753(14)00284-X [pii] LID - 10.1016/j.medcli.2013.11.041 [doi] AB - BACKGROUND AND OBJECTIVE: After an acute pulmonary embolism few long-term prognostic factors have shown to be of practical use. We hypothesized that, as in heart failure, natriuretic peptides could serve as biomarkers of a late deleterious prognosis. PATIENTS AND METHODS: Consecutive patients admitted to an Internal Medicine ward diagnosed with acute pulmonary embolism were traced through the computerized system of clinical episodes of Navarra Health System and by telephone calls. On hospitalization, standard evaluation was made, previous history of cancer and cardiac disease was recorded, and N-terminal ProB-type natriuretic peptide (NT-ProBNP), D-dimer and Troponin I were measured. In the analysis all-causes death was considered. RESULTS: Two hundred and thirty-four patients were traced, median age 75 [interquartile range (IQR) 16] years old, women 51%. At a median time of 9.5 (IQR 29) months 52 (22%) patients had died, 38 (73%) dead patients had NT-ProBNP higher than 850 ng/L. NT-ProBNP in dead patients was 2.741 (IQR 7.420)ng/L and 662 (IQR 2.517)ng/L in survivors (p<0.001). Age (OR 4.37 CI 95% 1.04-1.16) and NT-ProBNP (OR 1.49 CI 95% 1-1.002) showed to be independent factors of mortality. Between the 3rd and 20th month after the diagnosis, a level of NT-ProBNP higher than 850 ng/L (sensitivity 0.86, specificity 0.45 and negative predictive value 0.92) was associated with a lower survival (p=0.019), hazard ratio 1.89, OR 7.67 (CI 95% 1.52-39.44) for this period. CONCLUSION: Besides the unchangeable age, plasma level of NT-ProBNP measured on acute pulmonary embolism could predict longer-term all-cause death. CI - Copyright (c) 2013 Elsevier Espana, S.L.U. All rights reserved. FAU - Alonso-Martinez, Jose Luis AU - Alonso-Martinez JL AD - Department A of Internal Medicine, Hospital Complex of Navarra, Irunlarrea 6, 31008 Pamplona, Spain. Electronic address: jalonsom@cfnavarra.es. FAU - Anniccherico-Sanchez, Francisco Javier AU - Anniccherico-Sanchez FJ AD - Department A of Internal Medicine, Hospital Complex of Navarra, Irunlarrea 6, 31008 Pamplona, Spain. FAU - Urbieta-Echezarreta, Miren Aranzazu AU - Urbieta-Echezarreta MA AD - Department A of Internal Medicine, Hospital Complex of Navarra, Irunlarrea 6, 31008 Pamplona, Spain. FAU - Perez-Ricarte, Sara AU - Perez-Ricarte S AD - Department A of Internal Medicine, Hospital Complex of Navarra, Irunlarrea 6, 31008 Pamplona, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20140616 PL - Spain TA - Med Clin (Barc) JT - Medicina clinica JID - 0376377 RN - 0 (Biomarkers) RN - 0 (Peptide Fragments) RN - 0 (pro-brain natriuretic peptide (1-76)) RN - 114471-18-0 (Natriuretic Peptide, Brain) SB - IM MH - Acute Disease MH - Adult MH - Aged MH - Biomarkers/blood MH - Female MH - Follow-Up Studies MH - Humans MH - Logistic Models MH - Male MH - Middle Aged MH - Natriuretic Peptide, Brain/*blood MH - Peptide Fragments/*blood MH - Prognosis MH - Pulmonary Embolism/blood/diagnosis/*mortality MH - Sensitivity and Specificity OTO - NOTNLM OT - Biomarcadores OT - Biomarkers OT - N-terminal ProB-type natriuretic peptide OT - Prohormona N-terminal del peptido natriuretico cerebral OT - Pulmonary embolism OT - Riesgo de mortalidad OT - Risk of death OT - Tromboembolismo pulmonar EDAT- 2014/06/21 06:00 MHDA- 2015/12/15 06:00 CRDT- 2014/06/21 06:00 PHST- 2013/08/12 00:00 [received] PHST- 2013/11/02 00:00 [revised] PHST- 2013/11/07 00:00 [accepted] PHST- 2014/06/21 06:00 [entrez] PHST- 2014/06/21 06:00 [pubmed] PHST- 2015/12/15 06:00 [medline] AID - S0025-7753(14)00284-X [pii] AID - 10.1016/j.medcli.2013.11.041 [doi] PST - ppublish SO - Med Clin (Barc). 2015 Mar 15;144(6):241-6. doi: 10.1016/j.medcli.2013.11.041. Epub 2014 Jun 16.